actinomycin D (AD), the anthracyclines adriamycin (ADR) and daunorubicin (DNR), the semisynthetic podophyllotoxin (VP16) and the Vinca alkaloids vincristine (VC) and vinblastine (VBL) (see Table I ). Cross-resistance has been demonstrated both in vitro (Biedler & Riehm, 1970; Nishimura et al., 1978; Baskin et al., 1981) and in vivo (Kessel et al., 1968; Dano, 1972; Kaye & Bowden, 1980; Chitnis et al., 1982; Seeber et al., 1982) and in general the cross-resistance does not extend to other drugs.
This phenomenon, known as pleiotropic drug resistance, is interesting because of the structural and biological dissimilarity of these drugs. It is possible that a common mechanism underlies the emergence of resistance to these compounds which may have important consequences in the clinical treatment of cancer using chemotherapy.
Data from human tumours are limited. There are few clinical data regarding the emergence of pleiotropic drug resistance, but it is a general impression that when resistance to a cytotoxic drug regimen develops clinically, even though it is possible to identify other regimens which have short-lived activity, universal drug resistance usually ensues. However the clinical situation is a complex one since cytotoxic drugs are generally given in combination, which makes the recognition of any particular pattern of cross resistance unlikely.
Data from human cell lines in culture are also limited and it remains unclear whether crossresistance between antibiotics, anthracyclines, VP16-213 and Vinca alkaloids is a common finding in vitro. Beck (1983) (Heppner & Shapiro, 1983 Cell lines were obtained from human glioma as described previously (Morgan et al., 1983 Glasgow, U.K.). All the cell lines grew as monolayers in culture.
The growth medium used for the cell cultures was Ham's FIO supplemented with Eagle's MEM non-essential amino acids (Flow Laboratories), 50 units ml-I benzyl penicillin, 50 jug ml-1 streptomycin sulphate and with a gas phase of 5% C02. The medium was supplemented with 10% foetal bovine serum (Flow Laboratories).
The drugs used in this study were adriamycin (Farmitalia Carlo Erba Ltd, Barnet, Herts, U.K.), actinomycin D (trade name "Lyovac Cosmegen", Merk Sharp and Dohme International, Rahway, NJ, U.S.A.), vincristine sulphate (trade name "Oncovin", Eli Lilly and Co. Ltd, Basingstoke, U.K.), VP16-213 (trade name "Vepesid", Bristol Myers Pharmaceuticals, Slough, U.K.), 5-fluorouracil (Roche Products Ltd, Welwyn Garden City, U.K.) and L-phenylalanine mustard (melphalan, trade name "Alkeran", The Wellcome Foundation Ltd, London, U.K.). They were diluted according to manufacturers' instructions for injection and stored at -20°C until required (no longer than 1 month after freezing). They were then further diluted in culture medium to the required concentrations. In the case of L-PAM care was taken to ensure that these operations were carried out within 30 min because of the instability of the drug. In no case did the volume of diluent added with the drug exceed 1% of the final volume. Radiochemicals were obtained from Amersham International PLC (Amersham, Bucks, U.K.).
Drug sensitivity assays were carried out using a modifiaction of a method described previously (Morgan et al., 1983 (Morgan et al., 1983) .
In all drug experiments, cell counts (using a model ZB, Coulter Counter) were made of replicate plates of each cell line to determine population doubling time and to ensure that the control cultures remained in exponential growth throughout the period of drug-treatment and recovery. The period of drug exposure of 72 h exceeded one population doubling time with all of the cell lines used in these experiements.
At the end of the experimental cell number was assayed by exposing the cells to medium containing 3 1iCi ml-1 [35S]-methionine (specific activity 638-1275 Ci mmol-1) or 1 ICi ml -1 L-4,5-[3H]-leucine (specific activity 10mCi mol -1) for periods of between 4j and 24 h. During this period the rate of incorporation of labelled amino acid has been shown to be linear (Freshney et al., 1975) . The plates were then washed and cell protein (solubilised in 1 M NaOH) counted as previously described (Freshney et al., 1975) . The incorporation of labelled amino acid of each well was expressed as a percentage of the control in that row and the dose of drug that inhibited protein synthesis by 50% (ID50) determined.
The cell lines are ranked in order of sensitivity (ID50) to each drug in Table II Statistical analysis of the data was carried out using Kendall's coefficient of concordance (W) (Siegel, 1956) . The null hypothesis is that there is no correlation between the ranking of sensitivity for the six cell lines. The value of W for the entire table is 0.5 (P<0.01) and although this value is highly significant it can be improved to 0.7 by the exclusion of 5-FU from the calculations, to 0.8 by the exclusion of L-PAM and 5-FU, and 1.0 by the exclusion of ADR, L-PAM and 5-FU. These results confirm the apparent relationship between the sensitivities of the cell lines to AD, VP16 and VC. time (h) (x J'-10M)(x 10-7M)(x10-9M)(x 10-8M) (x 10-6M) (x 10-6M) G-CCM 3.5 2 3.5 3.5 2 5.5 G-UVW 3.5 3.5 3.5 3.5 1 5.5 G-IJK 3.5 3.5 3.5 3.5 3 2 G-RM 3.5 5.5 3.5 6 5.5 4 G-MCN 6 5.5 6 3.5 5.5 2 value of their rankings in Table II (Siegel, 1956 (Sethi et al., 1981) and 7-701iM for VP16 (Creaven, 1982 (Beck, 1983) and possibly small cell lung cancer cell lines (Shoemaker et al., 1983) , and both in vitro and in vivo in animal tumour models (Table I) (Tsuro et al., 1982) 
